Literature DB >> 12784853

Physiologic melatonin concentration, omega-3 fatty acids, and conjugated linoleic acid inhibit fatty acid transport in rodent hind limb skeletal muscle in vivo.

Robert T Dauchy1, David E Blask, Leonard A Sauer, Leslie K Davidson, Jean A Krause, Laura C Smith, Erin M Dauchy.   

Abstract

Melatonin (MLT), the circadian neurohormone secreted by the pineal gland in mammals during darkness, eicosapentanoic acid (EPA), and conjugated linoleic acid (CLA) have established regulatory roles in cancer growth. Investigations in our laboratory have indicated that these agents inhibit fatty acid (FA) transport by tumors and several sub-types of white adipose tissue via inhibitory G protein-coupled receptor mechanisms. Skeletal muscle constitutes over 45% of human body mass and plays an important role in cancer cachexia and obesity-related diseases. Since fatty acid oxidation is a major source of energy for this tissue, we tested the hypothesis that physiologic MLT levels, EPA, or CLA injected intravenously, inhibit FA uptake in rat skeletal muscle in vivo. We used a surgical technique for catheterizing the femoral vein in rats that allows rapid blood collection from the entire hind limb, while ensuring continuous blood flow to the tissue. Blood acid/gas tensions and hematocrit were monitored and remained constant during the course of each experiment. The MLT, EPA, and CLA inhibited FA uptake by the tissue and lowered cAMP values. Glucose uptake and glycerol production in the hind limb were not affected. These investigations suggest a novel role for MLT, omega-3 FAs, and CLA in the regulation of FA transport and fat metabolism in skeletal muscle.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12784853

Source DB:  PubMed          Journal:  Comp Med        ISSN: 1532-0820            Impact factor:   0.982


  5 in total

1.  Effects of melatonin supplementation on disease activity, oxidative stress, inflammatory, and metabolic parameters in patients with rheumatoid arthritis: a randomized double-blind placebo-controlled trial.

Authors:  Alireza Khabbazi; Aida Malek Mahdavi; Kamal Esalatmanesh; Amirhossein Loghman; Roozbeh Esalatmanesh; Zahra Soleimani; Seyed Gholam Abbas Mousavi
Journal:  Clin Rheumatol       Date:  2021-03-05       Impact factor: 2.980

Review 2.  Putting cancer to sleep at night: the neuroendocrine/circadian melatonin signal.

Authors:  David E Blask; Robert T Dauchy; Leonard A Sauer
Journal:  Endocrine       Date:  2005-07       Impact factor: 3.633

3.  Intake of melatonin is associated with amelioration of physiological changes, both metabolic and morphological pathologies associated with obesity: an animal model.

Authors:  Mahmoud R Hussein; Omyma G Ahmed; Asmaa F Hassan; Marwa A Ahmed
Journal:  Int J Exp Pathol       Date:  2007-02       Impact factor: 1.925

4.  A new apparatus and surgical technique for the dual perfusion of human tumor xenografts in situ in nude rats.

Authors:  Robert T Dauchy; Erin M Dauchy; Lulu Mao; Victoria P Belancio; Steven M Hill; David E Blask
Journal:  Comp Med       Date:  2012-04       Impact factor: 0.982

5.  International Union of Basic and Clinical Pharmacology. LXXV. Nomenclature, classification, and pharmacology of G protein-coupled melatonin receptors.

Authors:  Margarita L Dubocovich; Philippe Delagrange; Diana N Krause; David Sugden; Daniel P Cardinali; James Olcese
Journal:  Pharmacol Rev       Date:  2010-07-06       Impact factor: 25.468

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.